{"title":"激素难治性前列腺癌的化疗。","authors":"Johannes Maria Wolff","doi":"10.1159/000139884","DOIUrl":null,"url":null,"abstract":"<p><p>Research in the past 3 decades has resulted in new approaches to treat patients with hormone-refractory prostate cancer. Employing the new treatment options, we are now able to prolong survival in these patients. At present, docetaxel given on a 3-week schedule is the standard of care for patients with hormone-refractory prostate cancer. Several new treatments are under investigation in phase III trials and will further improve the treatment options for these patients within the next years.</p>","PeriodicalId":55140,"journal":{"name":"Frontiers of Radiation Therapy and Oncology","volume":"41 ","pages":"103-107"},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000139884","citationCount":"2","resultStr":"{\"title\":\"Chemotherapy in hormone-refractory prostate cancer.\",\"authors\":\"Johannes Maria Wolff\",\"doi\":\"10.1159/000139884\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Research in the past 3 decades has resulted in new approaches to treat patients with hormone-refractory prostate cancer. Employing the new treatment options, we are now able to prolong survival in these patients. At present, docetaxel given on a 3-week schedule is the standard of care for patients with hormone-refractory prostate cancer. Several new treatments are under investigation in phase III trials and will further improve the treatment options for these patients within the next years.</p>\",\"PeriodicalId\":55140,\"journal\":{\"name\":\"Frontiers of Radiation Therapy and Oncology\",\"volume\":\"41 \",\"pages\":\"103-107\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000139884\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers of Radiation Therapy and Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000139884\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Radiation Therapy and Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000139884","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chemotherapy in hormone-refractory prostate cancer.
Research in the past 3 decades has resulted in new approaches to treat patients with hormone-refractory prostate cancer. Employing the new treatment options, we are now able to prolong survival in these patients. At present, docetaxel given on a 3-week schedule is the standard of care for patients with hormone-refractory prostate cancer. Several new treatments are under investigation in phase III trials and will further improve the treatment options for these patients within the next years.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
